Position in NVCT
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$7
New position
Shares Held
1
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Allworth Financial LP holds $21,498,679 across 297 Biotechnology names. NVCT ranks #293 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
15,803 | $7,056,671 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
36,244 | $2,342,449 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,991 | $2,310,966 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
3,562 | $1,864,600 | |
| 5 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
26,462 | $655,199 | |
| 6 | CRSP |
CRISPR Therapeutics AG
|
11,016 | $524,031 | |
| 7 | INCY |
Incyte Corp
|
4,834 | $454,976 | |
| 8 | EXEL |
Exelixis, Inc.
|
10,084 | $432,502 |
All Filings in NVCT
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $7 | 1 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||